Skip to main content

Piflufolastat F 18 Pregnancy and Breastfeeding Warnings

Piflufolastat F 18 is also known as: Pylarify

Piflufolastat F 18 Pregnancy Warnings

This drug is not indicated for use in female patients.

US FDA pregnancy category: Not assigned

Risk Summary: There is no information on the risk of adverse developmental outcomes in pregnant women or animals with the use of this drug.

Comments:
-This drug is a radiopharmaceutical and has the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose.

This drug is not indicated for use in female patients.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Piflufolastat F 18 Breastfeeding Warnings

This drug is not indicated for use in female patients.

Excreted into human milk: Data not available
Excreted into animal milk: Data not available

Comments:
-There is no information regarding this drug on the presence in human milk, the effects on a breastfed infant, or effects on milk production.

See references

References for pregnancy information

  1. "Product Information. Pylarify (piflufolastat F-18)." Progenics Pharmaceuticals, Inc. (2022):

References for breastfeeding information

  1. "Product Information. Pylarify (piflufolastat F-18)." Progenics Pharmaceuticals, Inc. (2022):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.